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ALK and ROS1 Staining and InterpretationPersonalized medicine by appropriate targeting of molecular
targets in tumors has improved survival of patients with
nonesmall-cell lung cancer (NSCLC). Besides testing for
variants in the epidermal growth factor receptor gene, the
identification of rearrangements in anaplastic lymphoma
kinase (ALK ) and ROS proto-oncogene 1 (ROS1) genes is
required to select patients for treatment with tyrosine kinase
inhibitors.1
ALK and ROS1 rearrangements are mutually exclusive,
and occur in approximately 3% to 7% and 1% to 2% of
NSCLC cases, respectively.2 The most common fusion
partner for ALK includes the echinoderm microtubule-
associated protein-like 4 gene,3 whereas the CD74-ROS1
fusion occurs most frequently for ROS1. More than 20
fusion partners have been described for both ALK and
ROS1, but the clinical significance of different fusion
products requires further investigation.
To date, five ALK tyrosine kinase inhibitors (crizotinib,
ceritinib, alectinib, brigatinib, and lorlatinib) have received
approval by the US Food and Drug Administration (https://
www.fda.gov, last accessed July 20, 2020) and the European
Medicines Agency (https://www.ema.europa.eu/en/
medicines/download-medicine-data, last accessed July 20,
2020) for treatment of advanced ALK-positive NSCLC. In
2016 and 2019, crizotinib and entrectinib were approved
for the treatment of advanced ROS1-rearranged NSCLC,
respectively.4,5
Although fluorescence in situ hybridization (FISH)
testing was originally considered the gold standard, the
detection of increased protein expression to identify un-
derlying gene fusions by immunohistochemistry (IHC) is
currently widely accepted.6,7 Namely, IHC is reported to be
fast, cheap, and particularly useful in small biopsy speci-
mens with a limited number of neoplastic cells, and showed
a better correlation with clinical outcome.6e8
Several primary antibody clones are commercially avail-
able for ALK IHC. In 2016, the D5F3 antibody as part of
the ALK (D5F3) IHC CDx Assay (Roche, Ventana, Oro
Valley, AZ) received approval for the selection of ALK-
positive NSCLC, making ALK IHC a valuable alternative
compared with FISH testing.9 In contrast to antibodies using
a binary scoring system (eg, D5F3 IHC CDx), confirmation
of an intermediate ALK staining pattern is recommended for
antibodies using an intensity-based score (eg, 5A4 ALK
IHC), using FISH or other independent ALK-fusion detec-
tion assays.2,10,11 For the ALK1 antibody, conflicting results
are reported, as most studies found lower sensitivity of IHC
using ALK1 compared with D5F3 or 5A4.12 However, there
are some studies reporting higher sensitivity for ALK1
compared with the other antibodies.13
For ROS1, a single antibody clone (D4D6; Cell Signaling
Technology, Danvers, MA) was for some time the only
commercially available primary antibody, until the 1A1
(Origene, Rockville, MD) and the ROS1 SP384 antibody
(Roche, Ventana) were also introduced.14,15 Detection sys-
tems and other conditions of the protocols (eg, temperatureThe Journal of Molecular Diagnostics - jmdjournal.organd duration of incubation) reported in combination with
D4D6 have been shown to vary considerably,16 and cross-
platform studies are needed. As only part of the ROS1
IHC-positive cases are confirmed by ROS1 FISH positivity,
the IHC can be used for screening of ROS1-rearranged
NSCLC, but positive ROS1 IHC results should be
confirmed by a molecular or cytogenetic method.1 Because
of the rarity of ALK and ROS1 rearrangements, multiple
testing strategies are used in different countries, including
sequential testing of markers based on the clinical needs or
parallel testing using next-generation sequencing to enable
concurrent detection of as many potentially targetable mu-
tations as possible. Thus, ALK or ROS1 IHC is often per-
formed as a screening tool before FISH confirmation.1
Given the high incidence and mortality of lung cancer
(11.6% of total cancer cases and 18.4% of cancer-related
deaths) worldwide,17 of which 80% is accounted for by
NSCLC, the correct identification of ALK and ROS1 rear-
rangements is indispensable for appropriate treatment se-
lection. Even though recommendations and guidelines are
available, these are mainly general principles and do not
provide specific data required to help laboratories to eval-
uate the technical performance of IHC assays routinely used
for diagnostics.18e20
European external quality assessment (EQA) schemes
have been organized to evaluate the performance of ALK
and ROS1 IHC analyses and to assist laboratories in
generating accurate test results. EQA results showed room
for improvement with regard to the analytical outcome.21e23
Staining quality needs to be addressed with a focus on an-
tibodies and protocol parameters to allow identification of
required elements for appropriate staining and their relation
to analytical outcome. Several EQA schemes already indi-
cated a variety in ALK IHC protocols and detection
methods, both affecting EQA pass rates.10,20
This study evaluated staining performances from the
European Society of Pathology NSCLC EQA schemes be-
tween 2015 and 2018, independently performed by a team
of expert pathologists, for various ALK and ROS1 IHC
protocols and different laboratory characteristics. These
findings were compared with the sample outcomes as scored
by the participants, to assess how the scores awarded by the
experts translate into the participants’ interpretation.Materials and Methods
Four external quality assessment schemes were organized
for ALK IHC between 2015 and 2018, and three schemes
were organized for ROS1 IHC between 2016 and 2018. All
schemes were in accordance with ISO17043:2010 (confor-
mity assessment: general requirements for proficiency
testing, available from International Organization for Stan-
dardization, Geneva, Switzerland) and open to all labora-
tories worldwide. During every scheme, participating
laboratories received two unstained sections (3 mm thick)1439
Keppens et alfrom five NSCLC resection specimens or cell lines for
staining by their routine IHC protocol (Supplemental Table
S1). Participants were able to choose whether to use both
unstained slides for staining or use one slide as a spare or
negative control for the primary antibody. Samples were
validated beforehand by a central reference laboratory for
the IHC status and corresponding FISH status.
Participants were given 14 calendar days for staining and
interpretation. Participants were requested to return stained
slides for a central review. In 2015 and 2016, five cases
were requested for review. From 2017, the distribution of
the five cases occurred in three separate runs for ALK. In the
first run, three cases were sent, and one case was sent in the
second and third round. For ROS1, two separate runs were
organized in 2017 during which two and three cases were
sent for staining, respectively. As these runs were 2 to 4
months apart, only the slides from the run with three cases
were sent back for review. This was to ensure that all
samples were analyzed by the participants at a comparable
moment in time and were treated with an identical protocol,
and to reduce the administrative burden for participants by
sending multiple packages back to the coordination center.
Participants also completed an electronic datasheet with
their laboratory characteristics (such as their accreditation
status or setting) and details of detection protocols. In that
same sheet, participants had to provide their individual
scoring of the ALK and ROS1 expression in the EQA
samples (IHC status positive or negative, or analysis failure)
for each case, according to their routine protocol for inter-
pretation. The reported accreditation statuses and laboratory
settings (ie, university hospital, general hospital, or private
or industry laboratory) were validated afterwards on the
websites of the relevant national accreditation bodies and
the laboratory websites, respectively. Accreditation was
defined as adhering to ISO15189 (medical laboratories:
particular requirements for quality and competence, avail-
able from International Organization for Standardization),
ISO17025 (general requirements for the competence of
testing and calibration laboratories, available from
International Organization for Standardization), or relevant
national standards (such as CAP15189) (https://www.cap.
org/laboratory-improvement/accreditation/cap-15189-
accreditation-program, last accessed July 20, 2020), and
could include both specific accreditation for ALK or
ROS1 IHC or general laboratory accreditation for all
executed analyses.
Scoring criteria for the technical assessment were dis-
cussed beforehand by a team of experts in molecular
pathology (all pathologists; J.v.d.T, P.P., A.R., N.t.H,
K.M., and E.T.), and were based on a graded scale: 5,
excellent staining; 4, pass with minor remark; 3, defi-
ciency without affecting clinical output; 2, incorrect
staining with clinical output affected; and 1, failed
staining, impossible to interpret. Before scoring, one
round of harmonization was performed to ensure equal
assessment compared with several reference slides. A1440team of two to three pathologists scored the stained slides
simultaneously under a multihead microscope. An expert
staining score of 1 to 5 points (hereafter referred to as
ESS) was awarded based on the staining quality for all
the evaluated slides combined, relative to the optimal
staining pattern for the specific protocol used by the
participants. Control tissue was only taken into account if
sent back for review.
At the end of the EQA scheme, images of (sub)optimal
stains, their corresponding ESS, and protocols were made
available for the participants. They also received a general
scheme summary on the performance for the different
sample outcomes and ESS, and individual comments on the
staining quality were sent to each participant separately.
Statistics on these EQA scheme data were performed
using SAS software version 9.4 of the SAS System for
Windows (SAS Institute Inc., Cary, NC). Two generalized
linear models were used with estimation based on general-
ized estimating equations to account for clustering in the
data (ie, tests performed by the same laboratory). First,
proportional odds models were used to evaluate the asso-
ciation of laboratory characteristics (such as setting or
accreditation status) or used method (antibody, antigen
retrieval, or detection) with the ESS as ordinal outcome.
Results are presented by odds ratios (ORs) with 95% CIs.
The ESS, as assessed on the slides, is a combination of both
the used primary antibody clone and all subsequent protocol
steps, and the overall ESS values of the complete protocols
are presented. For the less common antibodies, protocols
were grouped into one category for statistical analysis, and
individual ESS scores are shown separately. The number of
EQA participations, samples tested per year, and involved
staff members in the complete test process were considered
as ordinal variables (instead of categorical) to evaluate the
influence of a þ1 level increase in these ordinal variables on
the ESS.
Second, Poisson models were used to analyze the asso-
ciation of the ESS from the assessors and the laboratory
characteristics, with the scoring of the participants, repre-
sented as the number of analysis failures, false-positive or
false-negative results, as count outcome variables. Only
cases for which both an ESS and an outcome scored by the
participants were available were taken into account. Results
are presented as incidence rate ratios (IRRs) with 95% CIs,
and taking into account the log of the total number of
samples analyzed during the EQA scheme as an offset
variable.
Results
Influence of Laboratory Characteristics on Expert
Staining Score
In total, data from 174 unique laboratories from 37 countries
were analyzed for ALK IHC (352 participations) and 82
unique participants from 26 countries for ROS1 IHC (137jmdjournal.org - The Journal of Molecular Diagnostics
Table 1 Average ESS for Laboratory Characteristics of the ALK and ROS1 EQA Scheme Participants
Laboratory characteristic
ALK (n Z 352) ROS1 (n Z 137)
n (%)
Average ESS
OR (95% CI) n (%)
Average ESS
OR (95% CI)
Samples tested in last 12 months 0.92 (0.76e1.11) NS 1.10 (0.88e1.38) NS
No clinical testing 10 (2.8) 4.6 9 (6.6) 3.6
<10 8 (2.3) 4.4 13 (9.5) 4.5
10e99 107 (30.4) 4.1 27 (19.7) 4.1
100e249 115 (32.7) 4.1 25 (18.3) 4.4
250e499 70 (19.9) 4.1 32 (23.4) 4.0
>500 38 (10.8) 4.2 19 (13.9) 4.3
Missing data 4 (1.1) 4.0 12 (8.8) 4.3
Staff involved in testingy 1.18 (0.96e1.45) NS 1.24 (0.91e1.70) NS
1e5 146 (41.5) 4.1 45 (32.8) 4.1
6e10 114 (32.4) 4.0 48 (35.1) 4.1
11e20 58 (16.5) 4.1 28 (20.4) 4.2
>20 25 (7.1) 4.6 12 (8.8) 4.4
Missing data 9 (2.6) 4.0 4 (2.9) 4.3
EQA participations 1.11 (0.91e1.36) NS 4.43 (2.62e7.48)***
First participation 175 (49.7) 4.1 82 (59.85) 3.9
Second participation 93 (26.4) 4.2 39 (28.47) 4.4
Third participation 59 (16.8) 4.3 16 (11.68) 4.9
Fourth participation 25 (7.1) 3.9 NAy NAz
EQA round **** ***
2015 73 (20.7) 3.7 NAy NAz
2016 91 (25.9) 4.2 31 (22.63) 4.0
2017 96 (27.3) 4.3 52 (37.96) 3.9
2018 92 (26.1) 4.1 54 (39.42) 4.5
Laboratory settingx{ NS NS
Industry 6 (1.7) 4.5 1 (0.7) 3.0
(Private) laboratories 55 (15.6) 4.2 6 (4.4) 4.0
Hospital laboratories 107 (30.4) 4.1 30 (21.9) 4.2
University and research 184 (52.3) 4.1 99 (72.3) 4.2
Missing data 0 (0.0) NA 1 (0.7) 4.0
Accreditation status{ NS *
No 172 (48.9) 4.1 40 (29.2) 3.9
Yes 175 (49.7) 4.2 87 (63.5) 4.3
Missing data 5 (1.4) 4.0 10 (7.3) 4.0
Proportional odds models with generalized estimating equations for clustering of the data were used to analyze the difference in ESS. The first three
characteristics (samples tested, staff involved, and EQA participations) are evaluated on an ordinal level. OR >1 represents a higher ESS for a higher category
level. OR <1 represents a lower ESS for a higher category level. Other characteristics are evaluated as a categorical variable: overall significance levels are
given. ORs for every pairwise comparison between categories are described in the main text.
*P < 0.05, ***P < 0.001, and ****P < 0.0001.
yAs the number of staff members involved in the complete test process was related to the number of samples tested annually, this characteristic was used as
a measure of the size of the laboratory and available expertise/resources.
zNo EQA scheme was organized to evaluate the ESS of ROS1 in 2015.
xIndustry are laboratories involved in the development of diagnostic commercial kits. (Private) laboratories are not within a hospital’s infrastructure.
Hospital laboratories included private and public hospitals. University and research included education and research hospitals, university hospitals, university
laboratories, and anticancer centers.
{Laboratory setting and accreditation were validated on the websites of the laboratories and national accreditation bodies. Accreditation was defined as
adhering to ISO15189 (medical laboratories: particular requirements for quality and competence, available from International Organization for Standardi-
zation, Geneva, Switzerland), ISO17025 (general requirements for the competence of testing and calibration laboratories, available from ISO), or relevant
national standards (such as CAP15189), specifically for the ALK or ROS1 test or a general laboratory accreditation.
ALK, anaplastic lymphoma kinase; EQA, external quality assessment; ESS, expert staining score; OR, odds ratio; NA, not applicable; NS, not significant; ROS1,
ROS proto-oncogene 1.
ALK and ROS1 Staining and Interpretationparticipations) (Supplemental Table S2). An overview of the
different laboratory characteristics and their relation to the
ESS is given in Table 1.The Journal of Molecular Diagnostics - jmdjournal.orgFor both markers, there was a significant improvement of
the average ESS depending on the EQA round. For ALK,
a higher ESS was observed in 2016 (OR, 2.34; 95%1441
Table 2 Average ESS for ALK and ROS1 IHC General Method Characteristics
Method characteristic
ALK (n Z 352) ROS1 (n Z 137)
n (%) Average ESS n (%) Average ESS
Method type *
Approved kit (CDx) 149 (42.3) 4.3 NAy NAy
LDT 203 (57.7) 4.0 137 (100.0) 4.2
Switched protocol between EQA schemesz NS NS
No 130 (36.9) 4.2 50 (36.5) 4.5
Yes 47 (13.4) 4.1 5 (3.6) 4.8
NAz 175 (49.7) 4.1 82 (59.9) 3.9
Antibody dilution NS NS
<1:50 67 (19.1) 4.3 13 (9.5) 4.5
1:50e1:100 79 (22.4) 4.0 89 (65.0) 4.2
>1:100 41 (11.7) 4.0 35 (25.6) 4.1
RTU 165 (46.9) 4.1 0 (0.0)
Incubation time, minutes ** NS
1e30 241 (68.5) 4.2 39 (28.5) 4.1
31e60 91 (25.9) 4.1 83 (60.6) 4.3
>60 19 (5.4) 3.6 15 (11.0) 3.9
Missing data 1 (0.3) 3.0 0 (0.0) NA
Incubation temperature, C ** *
Room temperature 114 (32.4) 4.1 49 (35.8) 4.0
1e40 219 (62.2) 4.2 85 (62.0) 4.3
>40 18 (5.1) 3.6 3 (2.2) 3.3
Missing data 1 (0.3) 3.0 0 (0.0) NA
Proportional odds models with generalized estimating equations for clustering of the data were used to analyze the difference in ESS as a categorical
variable: overall significance levels are given. Odds ratios (95% CIs) for every pairwise comparison between categories are described in the main text.
*P < 0.05, **P < 0.01.
yNo approved kit is currently available for ROS1 immunohistochemistry.
zA switch included the change in primary antibody, antigen retrieval, or detection kit. NA includes entries from first participations for which no method
information from previous rounds was available.
ALK, anaplastic lymphoma kinase; EQA, external quality assessment; ESS, expert staining score; IHC, immunohistochemistry; LDT, laboratory-developed test;
NA, not applicable; NS, not significant; ROS1, ROS proto-oncogene 1; RTU, ready to use.
Keppens et alCI, 1.39e3.95; P Z 0.0014), 2017 (OR, 3.64; 95%
CI, 2.11e6.29; P < 0.0001), and 2018 (OR, 2.17; 95% CI,
1.26e3.75; P Z 0.0056) compared with the first round in
2015. The ESS did not differ between any of the subsequent
rounds (2016 to 2018). For ROS1 IHC, there was a sig-
nificant improvement in ESS in the latest 2018 scheme
compared with 2016 (OR, 4.48; 95% CI, 1.87e10.75;
P Z 0.0008) and 2017 (OR, 4.85; 95% CI, 2.24e10.53;
P < 0.0001), but not between 2016 and 2017. An overview
of the comments provided to the participants for the awar-
ded ESS is shown in Supplemental Table S3.
Most participants were university and research labora-
tories for both ALK (52.3%) and ROS1 (72.3%) IHC, fol-
lowed by (general) hospital laboratories (30.4% and 21.9%
for ALK and ROS1, respectively). Private laboratories less
frequently performed ROS1 (4.4%) analyses compared with
ALK (15.6%) analyses. There was no significant difference
in the ESS depending on the laboratory’s setting.
Almost half of the laboratories (49.7%) were accredited
for ALK IHC testing according to ISO15189 or relevant
national standards, compared with 63.5% for ROS1 testing.
Only for ROS1 analysis, a higher ESS was observed for1442accredited participants (OR, 2.31; 95% CI, 1.15e4.65;
P Z 0.0191).
The number of staff members involved in the complete
IHC testing process (from sample receipt until readout) was
most frequently between 1 and 5 staff members for ALK
analysis (41.5%) and between 6 and 10 staff members for
ROS1 detection (35.1%). An increased number of involved
staff members resulted in a higher ESS, although the dif-
ference was not significant.
With regard to laboratory experience, there was no sig-
nificant relation between the number of samples tested
annually and ESS. For ROS1 analysis, ESS improved
significantly if a laboratory participated in more successive
EQA rounds (OR, 4.43; 95% CI, 2.62e7.48; P < 0.0001).
This was not the case for ALK analysis (P Z 0.3039).
Expert Staining Score for the Different Protocols
The relationship between the ESS and general IHC protocol
characteristics is described in Table 2. Overall, 57.7% of
ALK IHC tests were performed by a laboratory-developed
test (LDT), compared with 100.0% for ROS1 (as nojmdjournal.org - The Journal of Molecular Diagnostics
ALK and ROS1 Staining and Interpretationapproved kits were available at the time of this study). The
use of an approved kit according to the manufacturer’s in-
structions resulted in a better ESS for ALK (OR, 1.67; 95%
CI, 1.08e2.56; P Z 0.0201) in comparison to LDTs.
Performance was not affected by a switch in test method
(primary antibody, antigen retrieval, or detection platform)
between two schemes or the applied antibody dilution. In
contrast, lower average ESS values were observed for longer
incubation times and higher temperatures of the primary
antibody. In more detail, an incubation time of >60 minutes
negatively affected the ESS compared with a time between
31 and 60 minutes (OR, 0.45; 95% CI, 0.21e0.97;
P Z 0.0405) or between 1 and 30 minutes (OR, 0.31; 95%
CI, 0.17e0.60; P Z 0.0005) for the ALK primary antibody,
but not for ROS1 (PZ 0.0544). In total, 19 participants used
an incubation time of >60 minutes. For these participants, a
lower signal/noise ratio was observed (weak antigen detec-
tion along with high background). Most of these participants
(13/19) used the Ventana UltraView, i-view, or 1-view
detection method, and received an individual comment that
polymer detection is recommended. Of those 19 participants,
12 used less common antibodies, such as 5A4 (Abcam,
Cambridge, UK), which demonstrated lower performances.
Incubation temperatures <40C resulted in better ESS
compared with temperatures >40C (OR, 3.10; 95% CI,
1.51e6.34; P Z 0.0020) for ALK. For ROS1, on the
other hand, incubation at room temperature resulted in
lower performance compared with usage of a specific
temperature <40C (OR, 0.45; 95% CI, 0.23e0.86;
P Z 0.0160).
The ESS was also evaluated for the different combi-
nations of primary antibodies, antigen retrieval, and
detection platforms, as reported by the EQA participants.
ORs to obtain a good ESS for the most frequently used
combinations relative to other methods are visualized in
Table 3.
MostALK IHCparticipants (39.8%, nZ352) used theD5F3
ALK IHC CDx kit from Ventana, including the D5F3 antibody
clone in combination with the Cc1 kit and Optiview DAB IHC
detection kit. There was no significant difference in ESS be-
tween the most frequently used protocols. Also, the 1A4 clone
(Origene) displayed a higher ESS compared with most other
methods. Participants using the 5A4 (Novocastra, Nussloch,
Germany) antibody in combination with the Optiview, Bond, or
Envision flex detection kits demonstrated a good performance.
However, when using this antibody with other detection
methods, the 5A4 antibody resulted in a lower performance. A
similarly better performance was noticed for other antibodies
when using any of these three detectionmethods comparedwith
participants using the antibodies with other detection methods,
such as the ZytoChem method. Hence, the combination of the
applied antibody and detection system is important. An example
of optimal and suboptimal ALK IHC staining patterns for
different protocols is shown in Supplemental Figure S1.
There was also a significant difference between the
methods used for ALK antigen retrieval (P Z 0.0073).The Journal of Molecular Diagnostics - jmdjournal.orgLaboratory-developed EDTA or TRIS-EDTA based ap-
proaches performed significantly worse compared with the
commercial methods, such as Cc1 (Ventana) and Omnis
Envision FLEX TRS (Dako, Santa Clara, CA) (data not
shown). For antigen detection, laboratories using the
ZytoChem Plus (HRP) Polymer Kit (Zytomed)
performed suboptimal to all other reported detection kits
(P < 0.0001).
Of 137 tests, 131 (95.6%) for ROS1 were performed by the
D4D6 (Cell Signaling Technology) primary antibody, most
frequently (48.2%) in combination with the Cc1 kit and
Optiview DAB IHC detection kit from Ventana. ORs were all
>1, implying a higher ESS relative to all other methods used.
The ESS was significantly higher for the D4D6 clone in
combination with Optiview, compared with using the same
clone in combination with the UltraView Universal DAB
Detection kit or PT module TRS High envision Flex (Dako)
(Table 4). For ROS1, there were no observed differences be-
tween any of the other used protocols, or between the indi-
vidualmethods for antigen retrieval and detection.An example
of optimal and suboptimal ROS1 IHC staining patterns for the
D4D6 antibody in combination with the different platforms is
shown in Supplemental Figure S2. The number of users and
average ESS for the other primary antibodies are represented in
Table 5. ESS values are highly variable, with scores ranging
between 1.0 and 5.0 on a total of 5 points. The number of users
for these other primary antibodies is small, with minimum one
and maximum four laboratories applying the antibody.
Participants’ Scoring of ALK and ROS1 Expression in
the EQA Samples
In total, 1379 ALK cases and 470 ROS1 cases were
returned to the EQA provider for assessment of the ESS.
For ALK, incorrect interpretations (false-positive or false-
negative outcomes) and analysis failures (failure to stain
or interpret the slides) were observed in 34 (2.5%) and 19
(1.4%) cases, respectively. For ROS1, 4 (0.9%) mis-
interpretations and 6 (1.3%) analysis failures were
observed.
A lower staining performance, as determined by the ESS,
was significantly correlated to the incidence of analysis
misinterpretations or failures for the total number of ALK and
ROS1 cases tested (Figure 1). For ALK IHC, the false-
negative results are shown in Figure 1A and analysis fail-
ures in ALK expression negative cases are shown in
Figure 1B. For ROS1 IHC, lower ESS resulted in more false-
positive interpretations and more analysis failures in all
evaluated samples (Figure 1). The IRR for incorrect outcomes
in positive cases is not given as only one error was made.
The incidence of misinterpretations and analysis failures
for the above-mentioned laboratory characteristics is pre-
sented in Supplemental Table S4. Incorrect interpretations
for laboratories participating in the ALK subscheme
increased in later EQA rounds (IRR, 1.39; 95% CI,
1.02e1.90; P Z 0.0355). Analysis failures diminished1443
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Proportional odds models with generalized estimating equations for clustering of the data were used to analyze the difference in ESS. Differences in ESS are
represented as ORs (95% CIs) for every method (row level) relative to other methods used (column level). OR >1 represents a higher ESS for a given method
(column level) relative to the other method (row level). OR <1 represents a lower ESS for a method relative to other methods. Significant results are
highlighted in bold.
*P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001.
ALK, anaplastic lymphoma kinase; ESS, expert staining score; NA, not applicable; OR, odds ratio.
Keppens et alwhen a higher number of samples were tested annually
(IRR, 0.60; 95% CI, 0.44e0.83; PZ 0.0020), but increased
when laboratories switched from one protocol to another
one (IRR, 15.75; 95% CI, 1.65e150.71; P Z 0.0168).
For ROS1, the opposite was observed with fewer analysis
failures in later EQA rounds (IRR, 0.29; 95% CI,
0.09e0.91; P Z 0.0346) and more analysis failures when a
laboratory performs more ROS1 IHC samples annually in1444routine practice (IRR, 1.92; 95% CI, 1.25e2.93;
P Z 0.0027). If computed, there was no difference
depending on the number of previous participations, staff
members involved, or the accreditation status and technique
type (LDT versus in vitro diagnosticelabeled kit) used.
Because of the wide variety of different protocols and low
number of analysis misinterpretations and failures, IRRs for
each separate ALK and ROS1 IHCmethod were not analyzed.jmdjournal.org - The Journal of Molecular Diagnostics
Table 3 (continued)
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ALK and ROS1 Staining and InterpretationDiscussion
Immunohistochemistry has evolved into an indispensable
diagnostic tool for the selection of NSCLC patients for
targeted therapies, because of its low costs and fast turn-
around times.6 However, IHC is reported to lack standard-
ization, causing a risk of suboptimal technical performance,
which potentially leads to incorrect interpretations.24 This
study showed an improvement in staining performance over
time, with varying performance for the different protocols
for ALK IHC but not for ROS1. The staining performance
was affected by several laboratory characteristics. TheThe Journal of Molecular Diagnostics - jmdjournal.orgoutcome of the samples was influenced by the staining
performance as well as the participant’s interpretation.
Influence of Laboratory Characteristics on Expert
Staining Score
Our results clearly demonstrate the importance of EQA
participation in reaching high-quality staining for ROS1, as
laboratories obtained higher ESS when they participated in
successive EQA schemes. This suggests the educational
value of comparison to peers, the availability of individual
feedback on staining quality, and examples of good-quality1445
Table 4 ROS1 ESS for Different Combinations of Primary Antibodies, Antigen Retrieval, and Detection Kits














Cc1 (Ventana) OptiView DAB IHC Detection Kit
(Ventana)




13 (9.5) 3.8  0.7 b 0.29 (0.11e0.75)*
Omnis Envision FLEX
TRS, High pH (Dako)
Envision flex (Dako) 13 (9.5) 3.9  1.1 c 0.43 (0.15e1.23)
PT module TRS High
envision Flex (Dako)
10 (7.3) 3.8  0.6 d 0.24 (0.11e0.53)***





8 (5.8e) 4.1  0.6 e 0.50 (0.16e1.59)





11 (8.0) 4.0  0.9 f 0.70 (0.17e2.92)
Different combinations antigen retrieval/detection 10 (7.3) 3.9  0.9 g 0.77 (0.22e2.61)
Other antibodies (3) Different combinations antigen retrieval/detection 6 (4.4) 3.9  0.8 h 0.58 (0.13e2.62)
(table continues)
Proportional odds models with generalized estimating equations for clustering of the data were used to analyze the difference in ESS. Differences in ESS are
represented as ORs (95% CIs) for every method (row level) relative to other methods used (column level). OR >1 represents a higher ESS for a given method
(column level) relative to the other method (row level). OR <1 represents a lower ESS for a method relative to other methods. Significant results are
highlighted in bold.
*P < 0.05, ***P < 0.001.
ESS, expert staining score; LDT, laboratory-developed test; NA, not applicable; OR, odds ratio; ROS1, ROS proto-oncogene 1.
Keppens et alstains and protocols. Similar increased performances be-
tween rounds have also been reported for estrogen receptor
IHC by NordiQC,24 whereas they also observed a surprising
decrease in pass rate for ALK (https://www.nordiqc.org/
downloads/assessments/122_14.pdf, last accessed July 20,
2020). The lack of significant improvement for ALK might
be explained by the fact that laboratories have been
testing for this marker much longer and scores have
stabilized after 2015, coinciding with the introduction of
the ALK D5F3 CDx kit.
Recently, it was shown that accredited and research lab-
oratories, in comparison to nonaccredited laboratories, more
swiftly achieve a better performance during implementation
of novel markers in routine practice.25 The current study
demonstrated that accreditation also positively affects the
technical ROS1 staining quality, but no difference was
observed with regard to laboratory setting (research setting
versus private or community hospitals). Nevertheless, ROS1
seemed to be more frequently performed in research in-
stitutes than ALK, which was more frequently represented in
this EQA by laboratories based in general hospitals. In
addition, more staff members were involved for ROS1
compared with ALK IHC testing, even though this does not
mean that more individuals were involved in the interpre-
tation. As the number of staff members involved in the
complete test process was related to the number of samples
tested annually, this characteristic was used as a measure of
the size of the laboratory and available expertise/resources.1446The higher number of personnel involved for ROS1 can be
explained as the research institutes, which more frequently
tested ROS1 compared with other institutes, also reported to
have a higher number of staff members involved in the test.
This is in contrast to the general institutes, which more
frequently reported to only test for ALK and reported fewer
personnel. However, it cannot be excluded that the indi-
vidual completing the survey affected the responses
received. These findings may suggest that ROS1 IHC is
considered to require more follow-up and practice, although
more data are needed to investigate the interrelationship of
different laboratory characteristics. Nevertheless, labora-
tories are performing well for this marker and have
improved over time. Staining quality did not differ signifi-
cantly between the applied protocols.
ROS1 IHC readout has been reported to be more difficult
to interpret and operator dependent compared with ALK
IHC for several reasons. For instance, ROS1 expression can
be seen in a patchy pattern, typically at weak intensity in up
to a third of tumors that do not have an underlying rear-
rangement.1 Also, benign type 2 pneumocytes may show
focal positivity with ROS1, in contrast to ALK IHC, which
is negative in normal lung tissue.26
Expert Staining Score for the Different Protocols
This study confirmed the high variation in detection pro-
tocols applied by laboratories worldwide, with 16 differentjmdjournal.org - The Journal of Molecular Diagnostics
Table 4 (continued)
OR (95% CI) relative to
method
b c d e f g h
3.44 (1.33e8.90)* 2.34 (0.82e6.71) 4.12 (1.89e8.99)*** 1.99 (0.63e6.25) 1.43 (0.34e5.94) 1.31 (0.38e4.46) 1.73 (0.38e7.85)
NA 0.68 (0.19e2.44) 1.20 (0.43e3.34) 0.58 (0.15e2.17) 0.41 (0.09e2.01) 0.38 (0.10e1.51) 0.50 (0.10e2.49)
1.47 (0.41e5.26) NA 1.76 (0.56e5.54) 0.85 (0.20e3.51) 0.61 (0.12e3.20) 0.56 (0.13e2.44) 0.74 (0.14e3.95)
0.83 (0.30e2.33) 0.57 (0.18e1.79) NA 0.48 (0.15e1.60) 0.35 (0.08e1.52) 0.32 (0.09e1.13) 0.42 (0.09e1.88)
1.74 (0.46e6.54) 1.18 (0.29e4.90) 2.08 (0.63e6.90) NA 0.72 (0.13e3.96) 0.66 (0.14e3.04) 0.87 (0.16e4.88)
2.42 (0.50e11.77) 1.65 (0.31e8.62) 2.90 (0.66e12.82) 1.40 (0.25e7.69) NA 0.92 (0.16e5.29) 1.21 (0.18e8.33)
2.64 (0.66e10.53) 1.80 (0.41e7.87) 3.17 (0.89e11.36) 1.52 (0.33e7.04) 1.09 (0.19e6.29) NA 1.33 (0.23e7.75)
1.99 (0.40e9.90) 1.36 (0.25e7.25) 2.39 (0.53e10.75) 1.15 (0.21e6.44) 0.82 (0.12e5.64) 0.76 (0.13e4.42) NA
ALK and ROS1 Staining and Interpretationcommercial ALK antibodies used in combination with
several antigen retrieval methods and detection kits. US
Food and Drug Administration and European Conformity in
Vitro Diagnostic approved kits reached a higher ESS
compared with LDTs. This is in line with results reported by
NordiQC, where LDT performance for human epidermal
growth factor receptor 2 IHC improved over time but
remained suboptimal compared with approved tests,24 and
where adaptations by the laboratory to the ready-to-use
systems resulted in lower pass rates for ALK (https://www.
nordiqc.org/downloads/assessments/122_14.pdf, last
accessed July 20, 2020). An explanation could be that the
use of a US Food and Drug Administrationeapproved test
restricts the performing laboratory to a specified reagent set
and a closed protocol, and to an internal validation process
that provides some assurance of run-to-run stability. For
good laboratory practice, any deviation from the standard
reagents or protocol requires appropriate validation. De-
viations from the protocol have previously been shown to
have negative effects on the ability to demonstrate pro-
teins.27 However, in general, more cases were tested by
approved kits in the current study, which may have
contributed to the observed difference in performance.
Reasons for underperformance of LDTs might include the
lack of comparative literature on sensitivity and specificity
for less common antibodies, as well as unavailability of
training by the respective manufacturers.
The most widely used antibodies included D5F3
and 5A4. D5F3 (Ventana) is part of an in vitroThe Journal of Molecular Diagnostics - jmdjournal.orgDiagnosticelabeled kit. This antibody demonstrated
similar performances compared with the D5F3 clone from
another manufacturer (Cell Signaling Technology) and the
5A4 (Novocastra) clone. Results indicated a statistically
better performance for the 1A4 (Origene) primary anti-
body, even though this antibody has previously been re-
ported to have a lower specificity compared with D5F3.2
In case of equivocal results by 1A4, confirmation by an
additional independent method has therefore been
advised.2 However, compared with the percentage of
D5F3 users (39.8%), the percentage of 1A4 users is
relatively small (5.4%), and more data are needed to
confirm this statement. In contrast, it appeared that
application of less common antibodies, such as 5A4
(Abcam), ALK1 (Dako), or ALK01 (Ventana), resulted in
a lower ESS. For ALK1, this is not surprising, as several
studies demonstrated the lower performance for this clone,
and this clone is therefore not recommended for use in
NSCLC.1,28 These findings are in line with quality
assessment results from NordiQC and UK National
External Quality Assessment Scheme, where lower per-
formances were observed for ALK1.10 It must be taken
into consideration that the ESS as assessed on slides is a
combination of both the used primary antibody clone and
all subsequent protocol steps. This is the reason to present
the difference in overall ESS in Table 3.
A difference in antibody performance could therefore
also be attributed to the method of antigen retrieval and
detection systems. Indeed, this was exemplified by the1447
Table 5 Average ESS for Less Common ALK and ROS1 IHC Protocols
Antibody Antigen retrieval Detection platform Users, n Users, %
Average ESS
(on 5 points)
ALK (n Z 352)





Cc1 (Ventana) UltraView Universal DAB Detection kit
(Ventana)
1 0.3 4.0







Cc1 (Ventana) OptiView DAB IHC Detection Kit
(Ventana)
3 0.9 4.3
UltraView Universal DAB Detection kit
(Ventana)
1 0.3 3.0
LDT EDTA or TRIS-EDTA (with/
without pressure cooker)





Cc1 (Ventana) UltraView Universal DAB Detection kit
(Ventana)
1 0.3 3.0
5A4 (Histofine) HISTOFINE ALK Detection KIT HISTOFINE ALK Detection KIT 1 0.3 4.0
5A4 (Medac) LDT EDTA or TRIS-EDTA (with/
without pressure cooker)
ZytoChem Plus (HRP) Polymer Kit
(Zytomed)
1 0.3 3.0
5A4 (Monosan) Cc1 (Ventana) OptiView DAB IHC Detection Kit
(Ventana)
5 1.4 4.4
DAKO Omnis Envision FLEX TRS, High
pH
Envision flex (Dako) 1 0.3 5.0
5A4 (Zytomed) Cc1 (Ventana) OptiView DAB IHC Detection Kit
(Ventana)
2 0.6 3.5
DAKO Omnis Envision FLEX TRS, High
pH
Novolink Polymer Detection System
(Leica)
3 0.9 5.0
LDT EDTA or TRIS-EDTA (with/
without pressure cooker)
ZytoChem Plus (HRP) Polymer Kit
(Zytomed)
1 0.3 3.0
1A4 (Zytomed) Cc1 (Ventana) UltraView Universal Alkaline
Phosphatase Red Detection Kit
(Ventana)
1 0.3 4.0
LDT EDTA or TRIS-EDTA (with/
without pressure cooker)
ZytoChem Plus (HRP) Polymer Kit
(Zytomed)
1 0.3 2.0
ALK01 (Ventana) Cc1 (Ventana) OptiView DAB IHC Detection Kit
(Ventana)
4 1.1 3.0
UltraView Universal DAB Detection kit
(Ventana)
1 0.3 2.0
ALK1 (Dako) Bond Epitope Retrieval 1 (Leica) Bond polymer refine detection system
(Leica)
1 0.3 1.0
Cc1 (Ventana) OptiView DAB IHC Detection Kit
(Ventana)
1 0.3 4.0
DAKO Omnis Envision FLEX TRS, High
pH
Envision flex (Dako) 1 0.3 2.0
EnVisionFLEX Target Retrieval
Solution, low pH (Dako Omnis)
1 0.3 1.0
ROS1 (n Z 137)
D4D6 (Bioké) Cc1 (Ventana) OptiView DAB IHC Detection Kit
(Ventana)
1 2.9 3.0
EP282 (Epitomics) 3 8.6 4.7
D4D6 (Genemed) UltraView Universal DAB Detection kit
(Ventana)
2 5.7 4.0
During the external quality assessment scheme, an ESS of 3 on a total of 5 points was considered acceptable.
ALK, anaplastic lymphoma kinase; ESS, expert staining score; IHC, immunohistochemistry; LDT, laboratory-developed test; ROS1, ROS proto-oncogene 1.
Keppens et allower ESS for homebrew antigen retrieval reagents and
the ZytoChem Plus (HRP) Polymer Kit (Zytomed, Barg-
teheide, Germany) for detection of ALK. Also, the 5A41448(Novocastra) performed equally well as other primary
antibodies in combination with the three most common
detection kits [OptiView DAB IHC Detection Kitjmdjournal.org - The Journal of Molecular Diagnostics
Figure 1 Average anaplastic lymphoma kinase (ALK ) and ROS proto-oncogene 1 (ROS1) expert staining score (ESS) related to participants’ scoring
incidence of false positives/false negatives (A) and analysis failures (B). Bar labels represent the number of cases with or without incorrect interpretations/
analysis failures observed. Poisson models with generalized estimating equations were used to analyze the association of the ESS with the number of incorrect
interpretations (false-positive and false-negative results; A) and the number of analysis failures (B) by the participants, observed in the external quality
assessment (EQA) schemes as count outcome variables. Results are presented as incidence rate ratio (IRR) (95% CI), taking into account the log of the total
number of samples analyzed during the EQA scheme as an offset variable. IRRs <1 represent a lower number of incorrect interpretations or analysis failures for
higher ESS. The IRR for incorrect interpretations in ROS1-positive cases was not computed as only one error occurred. **P < 0.01, ***P < 0.001, and
****P < 0.0001. ND, not determined.
ALK and ROS1 Staining and Interpretation(Ventana), Envision Flex (Dako), or Bond polymer refine
detection system (Leica, Nussloch, Germany)], but worse
when using less common detection methods (Table 3).
The participants with an incubation time >60 minutes
also used antibody clones that demonstrated a lower
performance in this study.
For the incubation temperature, it might be useful to
evaluate the difference between 32C and 36C to 37C in
future schemes, as they represent frequently used cutoffs in
routine practice. This was not performed in this study as the
number of laboratories using 32C was too low to make
valid assumptions (9/351 for ALK and 4/137 for ROS1).
Because not all participants provided their in-house
control tissues, these were not evaluated and might be
considered a limitation of this study. The use of appropriate
positive and negative controls by participants to evaluate the
sensitivity and specificity of the tests is advised and has
previously been reported to be highly variable and often
suboptimal.10 In the currently ongoing EQA scheme, an
additional request was made to the participants to submit
control tissues/slides as well. Also, the next schemes will
allow an evaluation of the ROS1 SP384 (Ventana) or 1A1
(Origene)14,15 antibodies, which were not yet available
during the time of the EQA schemes interrogated for this
study.
In contrast to ALK IHC, no European Conformity in
Vitro Diagnostic certified method was available for ROS1
analysis at the time of these EQA schemes. Most partici-
pants (95.6%) used the D4D6 antibody (Cell Signaling
Technology). A variety of protocols were reported, although
most frequently in combination with OptiView DAB IHC
Detection Kit (Ventana) (Table 4). This combination
revealed a better performance compared with other test
methods, although only significant compared withThe Journal of Molecular Diagnostics - jmdjournal.orgUltraView and PT module TRS High envision Flex (Dako).
It is notable that a few laboratories reported the use of other
clones, including D4D6 (Genemed, Torrance, CA), D4D6
(Bioké, Leiden, the Netherlands), and EP282 (Epitomics,
Cambridge, UK), and these did not differ compared with
D4D6 (Cell Signaling Technology) concerning the ESS.
ROS1 testing has been more recently introduced than ALK,
and international testing guidelines were first made available
in 2016.29 As such, less information is currently available
compared with ALK, and more interlaboratory studies are
needed on the performance of detection protocols.
Participants’ Scoring of ALK and ROS1 Expression in
the EQA Samples
As a lower staining performance (as defined by the ESS)
resulted in an increased rate of misinterpretations, technical
schemes can be useful in guiding participants in further
optimizing their detection protocol through individually
tailored feedback, ultimately also resulting in an improve-
ment in their scoring. Detection of positive cases (which
might be rare in case of ALK and ROS1 rearrangements in
NSCLC) is of utmost importance, as a false-negative
outcome could result in the loss of chance to benefit from
optimal treatment for patients.4 False-positive results, on the
other hand, still have a chance to be corrected in case FISH
confirmation is performed, which is not required in case of
using an approved ALK IHC method.
The overall number of false-positive and false-negative
results observed in the EQA schemes was low, with 34 of
1379 (2.5%) for ALK and 19 of 470 (4.0%) for ROS1. Sur-
prisingly, the number of total incorrect ALK IHC in-
terpretations was significantly higher (P Z 0.0355) for later
EQA scheme years, but not when evaluating positive and1449
Keppens et alnegative samples separately. This was explained by the fact
that in the later scheme years, two laboratories made multiple
interpretation errors on the set of five or three samples,
affecting both positive and negative cases. In 2016, these
laboratories denoted all five samples as negative or positive,
respectively, suggesting a problem with their IHC interpre-
tation criteria and cutoff. In 2017, both laboratories switched
the interpretation for a positive and negative case. In other
scheme years or for ROS1 IHC, only one error per laboratory
was made. As the overall misinterpretations were low, these
two laboratories with multiple errors have skewed the data
toward higher error rates in later schemes, even though the
number of laboratories making an error remained stable.
Because of the low percentage of incorrect test in-
terpretations reported by participants, statistics on the inci-
dence of these errors were not calculated for different
protocols. However, for LDTs, 3.5% (25/802 for ALK and
19/470 for ROS1) of misinterpretations occurred compared
with 1.6% for CDx methods (9/577, ALK only).
Besides incorrect false-positive or false-negative sample
scoring, technical failures (failed run or suboptimal staining
leading to the inability to safely interpret the staining pattern)
were significantly related to the ESS. Indeed, a change in the
test protocol within the last 12 months introduced more
analysis failures for the concerned participants (Supplemental
Table S3), and this suggests the need for careful quality
control in case of newly introduced methods.
Repeated testing might cause additional costs, a delay in
the final diagnosis, loss of tissue, and, in cases where the test
cannot be repeated because of lack of material (as biopsy
specimens from NSCLC tumors are often minimal in ma-
terial), patient distress because of the need for an additional
intervention.
In this study, a decrease in errors/technical failures was
observed for both markers depending on the number of
samples tested annually. This is consistent to previously
reported findings in which the probability to have a suc-
cessful EQA score increased when a higher number of
samples was tested annually for KRAS, NRAS, or EGFR
mutation status.25 Thus, even though the staining quality
was not affected by a laboratory’s experience (annual test
volume) in this study, the interpretation of the staining in-
tensity is influenced by experience. Even if the IHC test is
completely standardized, interpretation is likely to always be
subjective, in part because it requires comparison with
appropriate controls, and these may differ for the various
antibodies and detection kits used.Conclusion
To conclude, a good ESS in the EQA scheme only repre-
sents one aspect of the total quality assurance system for
IHC, and might not fully reflect staining quality and con-
sistency in routine practice. Nevertheless, this study was
able to reveal the high variability of IHC methods, where the1450use of restricted protocols by approved kits led to improved
performance, in contrast to lower performances for less
commonly used protocols. In addition, although ALK testing
seems to be well implemented in general practice, ROS1
detection is still improving. More interlaboratory studies are
needed to assess performance for different ROS1 IHC
protocols. The correlation between the experts’ scoring and
participants’ interpretation, and variable effects of labora-
tory characteristics on both aspects, stress the importance for
EQA providers to evaluate both the staining quality and the
interpretation of the staining.Acknowledgments
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